Low Blood Sugar and Retatrutide: Trial Data

Low blood sugar (hypoglycaemia) is a clinically relevant consideration in retatrutide trials, particularly for participants receiving background insulin or sulphonylurea therapy. Retatrutide is an investigational triple receptor agonist with no marketing authorisation in the UK or elsewhere, and it is available only within authorised clinical trials. This article summarises what trial data report about hypoglycaemia risk, who is most at risk, what the warning signs are, and what to do if symptoms occur, drawing on named trial publications and UK clinical guidance.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide has no marketing authorisation in the UK or elsewhere and is available only to participants within authorised clinical trials. It is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) being studied for obesity and type 2 diabetes.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it is available only to clinical trial participants under the study protocol as an investigational medicinal product.^[17][1] It is being studied for the management of obesity and type 2 diabetes. Unlike licensed treatments such as tirzepatide (Mounjaro) or semaglutide (Wegovy), retatrutide is not available through NHS prescribing or private clinics outside of a formal research setting.

Retatrutide works by activating three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonist mechanism distinguishes it from currently authorised dual or single agonist medicines. The glucagon receptor component is thought to influence energy expenditure and hepatic glucose output, which has implications for blood sugar regulation.^[11][12]

Because retatrutide is investigational, the evidence base comes from named clinical trials rather than a licensed product dossier. The Phase 2 programme published in the New England Journal of Medicine in 2023 provided early data on efficacy and safety. The Phase 3 TRIUMPH programme (TRIUMPH-1 to TRIUMPH-4) and the TRANSCEND-T2D-1 trial have since reported further findings at major diabetes congresses and in peer-reviewed publications.^[3][2] Anyone seeking information about participation in a trial should speak to their GP and may also search for authorised recruiting studies via the NIHR Be Part of Research portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov. Anything sold online as retatrutide is not a licensed product and may be falsified or unsafe.

Who is most at risk of hypoglycaemia in retatrutide trials?

Trial participants using concomitant insulin or sulphonylureas are at greatest risk of hypoglycaemia. In participants not using these agents, the risk of clinically significant hypoglycaemia was considerably lower.

Participants in retatrutide trials who were also taking insulin or a sulphonylurea were at the greatest risk of hypoglycaemia (low blood sugar).^[1][2] This pattern is consistent with what is observed across the GLP-1 receptor agonist class and reflects the additive glucose-lowering effects of combining agents that act through different mechanisms. In trial populations that did not use insulin or sulphonylureas, the risk of clinically significant hypoglycaemia was considerably lower.

The glucagon receptor agonist component of retatrutide introduces a pharmacological consideration not present with GLP-1 or dual GIP/GLP-1 agonists. Glucagon normally raises blood glucose by stimulating hepatic glucose release, so activating the glucagon receptor might theoretically provide some protection against hypoglycaemia; however, this remains a hypothesis based on the known mechanism of glucagon action, and the net effect on blood sugar depends on the balance of all three receptor actions.^[11][12] Trial data suggest that hypoglycaemia risk remains meaningful in people on background glucose-lowering therapy.

People with type 2 diabetes who have tightly controlled blood glucose, those with impaired awareness of hypoglycaemia, older adults, and those with renal impairment are generally considered higher-risk groups across glucose-lowering medicine classes. Trial protocols for retatrutide studies included provisions for dose adjustments or discontinuation of concomitant insulin or sulphonylureas to manage this risk. These are trial-specific safety measures and do not constitute prescribing guidance for a licensed medicine. If you are enrolled in a trial, do not adjust your insulin or sulphonylurea dose except under the direct instruction of your trial team. If you have questions about your own risk profile, the trial team is the appropriate point of contact.

What did clinical trials report about blood sugar side effects?

The Phase 2 trial and TRANSCEND-T2D-1 trial both identified concomitant insulin use as the primary factor associated with hypoglycaemia; most episodes were non-severe, though severe events were reported in some insulin-using participants.

The Phase 2 retatrutide trial published in the New England Journal of Medicine reported that hypoglycaemia events occurred more frequently in participants with type 2 diabetes who were receiving background insulin therapy than in those who were not.^[1] In the obesity cohort without diabetes, clinically significant hypoglycaemia was uncommon. These findings were reported as adverse events within the trial population and under trial conditions, and they cannot be generalised to predict what an individual outside a trial would experience.

The TRANSCEND-T2D-1 trial, published in The Lancet, provided additional data in a type 2 diabetes population and similarly identified concomitant insulin use as a key factor associated with hypoglycaemia events.^[2][18] Across both programmes, the majority of hypoglycaemia episodes were classified as non-severe. Severe hypoglycaemia, defined in the trials as an episode requiring third-party assistance for recovery, was reported in some participants on insulin.^[6]

Beyond hypoglycaemia, the trials reported gastrointestinal side effects, including nausea, vomiting and diarrhoea, as the most common adverse events, consistent with the GLP-1 receptor agonist component of the molecule. Acute pancreatitis has been reported in association with GLP-1 receptor agonist medicines as a class; for example, the UK Summary of Product Characteristics for tirzepatide (Mounjaro) notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, without quantifying the risk magnitude.^[5][4] As retatrutide is investigational, any suspected adverse events in trial participants should be reported to the trial team under the study protocol. Suspected side effects of medicines can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What are the warning signs of low blood sugar and when should you seek help?

Warning signs include shakiness, sweating, palpitations, dizziness, and confusion; loss of consciousness or failure to recover after initial treatment is a medical emergency requiring an immediate 999 call.

The warning signs of low blood sugar (hypoglycaemia) include shakiness, sweating, palpitations, pallor, hunger, dizziness, difficulty concentrating, and confusion. In severe cases, hypoglycaemia can cause loss of consciousness or seizures. Symptoms can vary between individuals, and some people, particularly those with long-standing diabetes or frequent hypoglycaemic episodes, may have reduced awareness of early warning signs.

If you are a trial participant and experience symptoms that you think may represent hypoglycaemia, follow the guidance provided by your trial team, as trial protocols include specific instructions for managing and reporting such events. As a general principle, mild to moderate hypoglycaemia is treated by consuming approximately 15 to 20 g of fast-acting carbohydrates, such as glucose tablets or a sugary drink, in line with NHS guidance.^[7][6] Blood glucose should be rechecked after 15 minutes and the fast-acting carbohydrate repeated if levels remain low, followed by a longer-acting carbohydrate snack once blood glucose has recovered.

If a person loses consciousness, cannot swallow, or does not recover after initial treatment, this is a medical emergency: call 999 immediately. If you are a trial participant, tell the ambulance crew or hospital clinicians that you are enrolled in a clinical trial and show them your trial identification card or study contact details, so that the trial team can be informed and any protocol-specific guidance followed. For urgent advice about symptoms that are concerning but not immediately life-threatening, NHS 111 is available 24 hours a day.

If you drive, be aware that the DVLA has specific guidance on fitness to drive for people at risk of hypoglycaemia.^[8][9] You should discuss your individual situation with your trial team or GP, and you can find the relevant rules at gov.uk/diabetes-driving.

Routine questions about blood sugar management or your medicines should be directed to your GP or the clinical team overseeing your care. It is worth noting that retatrutide is available only within an authorised clinical trial. If you encounter any product being sold or promoted online as retatrutide, it is not a licensed medicine and may be falsified or dangerous. Do not use any such product, and report concerns to the MHRA.

Frequently Asked Questions